NTLA
Intellia Therapeutics Inc

13,142
Mkt Cap
$3B
Volume
5.09M
52W High
$28.25
52W Low
$5.90
PE Ratio
-5.97
NTLA Fundamentals
Price
$26.97
Prev Close
$27.98
Open
$27.60
50D MA
$15.62
Beta
1.76
Avg. Volume
6.42M
EPS (Annual)
-$5.25
P/B
4.12
Rev/Employee
$143,615.39
Loading...
Loading...
News
all
press releases
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?
Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus
Zacks' winning streak continues as UnitedHealth, Ovid and Micron deliver standout gains across key model portfolios.
Zacks·1d ago
News Placeholder
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·12d ago
News Placeholder
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·13d ago
News Placeholder
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know
The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·13d ago
News Placeholder
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?
Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Zacks·13d ago
News Placeholder
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.
Zacks·15d ago
News Placeholder
Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus
Zacks highlights winners like LendingTree, AutoZone, and Johnson & Johnson as its proven stock-picking strategies continue to shine.
Zacks·29d ago
News Placeholder
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
Zacks·1mo ago
News Placeholder
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks·1mo ago

Latest NTLA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.